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ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of 
chronic kidney disease in patients with type 1 diabetes. The aim of this study was to explore 
the relationship between markers of NAFLD, namely concentrations of aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-
glutamyltransferase (GGT), bilirubin and renal function in type 1 diabetic patients. Study 
included 313 normoalbuminuric type 1 diabetic patients with estimated glomerular filtration 
rate (eGFR) > 60 mlmin
-1
1.73m
-2
, without clinical evidence of cirrhosis or other causes of 
chronic liver disease and before any interventions with statins, ACE inhibitors or angiotensin 
II receptor blockers. ALT, GGT, and bilirubin levels were significantly higher in subjects in 
the highest quartile of serum creatinine compared to those in lowest quartile (21 vs 20 U/L, 18 
vs 14 U/L, and 14 vs 10 µmol/L, respectively, for all p<0.05). ALK levels were significantly 
higher in subjects in the highest quartile of urinary albumin excretion rate compared to those 
in lowest quartile (71 vs 69 U/L, p=0.03), as well as in hyperfiltrating subjects compared to 
those with normal or mildly impaired eGFR (81 vs 68 and 64 U/L, p<0.001). In a multiple 
logistic regression model adjusted for age, sex, duration of diabetes, HbA1c and BMI, only 
ALK levels were significantly associated with disturbances in serum creatinine and eGFR in 
our subjects (p≤0.007), with odds ratios of 0.98 to 1.02. NAFLD associated markers, 
particularly ALK, are associated with renal function in normoalbuminuric type 1 diabetic 
patients.  
 
Keywords: alkaline phosphatase, type 1 diabetes, renal function, nonalcoholic fatty liver 
disease  
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INTRODUCTION 
 Nonalcoholic fatty liver disease (NAFLD) is characterized by accumulation of fat in 
the liver and refers to a spectrum of disorders ranging from simple hepatic steatosis to more 
severe manifestations, including nonalcoholic steatohepatitis (NASH), in the absence of 
substantial alcohol consumption or other causes of liver disease such as viral hepatitis (1, 2). 
NAFLD is usually clinically silent, and most patients seek care because of an incidental 
finding of elevated aminotransferase levels or radiographic studies suggesting the liver is fat 
(3). Mildly to moderate elevated serum levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and γ-glutamyltransferase (GGT) are the most common abnormality 
found in patients with NAFLD (1, 4, 5). Serum alkaline phosphatase (ALK) exceed referent 
interval in many patients, although their degree of elevation is smaller than one seen in 
alcoholic hepatitis (6, 7). Hyperbilirubinemia can be also found in patients with NAFLD (8, 
9). Previously mentioned markers of liver injury may be surrogate measures of NAFLD and 
related conditions for larger studies (10, 11).  
 Patients with type 1 diabetes have a 20-50% probability of developing end-stage renal 
disease (12), and identification of the determinants of the onset of early diabetic nephropathy 
is essential for reducing the morbidity and mortality associated with diabetes. In recent years, 
the possible link between NAFLD and chronic kidney disease (CKD) has attracted scientific 
interest, because NAFLD and CKD share many important risk factors and both are linked to 
an increased risk of cardiovascular diseases (13-15). In patients with type 1 and type 2 
diabetes it was found that ultrasound-diagnosed NAFLD was associated with CKD (defined 
as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m
2 
or overt proteinuria), 
independently of traditional risk factors (16, 17). It was also found that NAFLD, diagnosed by 
ultrasound or liver biopsy, was associated with microalbuminuria in subjects with or without 
diabetes, independently of several potential confounders (18, 19). Moreover, it was found that 
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elevated serum liver enzyme levels, as surrogate markers for NAFLD, were independently 
associated with an increased incidence of CKD (20-22).  
 Little is known about the relationship between NAFLD markers and change in renal 
function among individuals with normal or mildly impaired renal function, because most 
studies have focused on the progression of established renal disease. The objective of this 
study was to investigate relationship between NAFLD associated markers and renal function 
parameters in normoalbuminuric type 1 diabetic patients with normal or mildly impaired renal 
function (eGFR > 60 ml/min/1.73m
2
).  
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SUBJECTS, MATERIALS AND METHODS 
 This study included 313 patients with diabetes mellitus type 1. Type 1 diabetes was 
defined as an onset of diabetes before the age of 35 years, positive autoantibodies and 
permanent insulin treatment initiated within 1 year of diagnosis. The study included patients 
with following characteristics: age of 18-65 years, minimum duration of type 1 diabetes for 1 
year, no medical history of liver, renal and cardiovascular diseases, absence of any systemic 
disease, and absence of any infections in the previous month. Patients who had reported daily 
alcohol intake exceeding 20 g/day were excluded from the study. None of patients had 
serological and clinical evidence of viral hepatitis, hemochromatosis, Wilson disease, 
autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis or biliary obstruction, 
hepatitis B or C virus infections, and none of them were intravenous drug addicts. Patients 
were excluded from the study if they took any of the following: lipid-lowering therapy, 
antihypertensive therapy including ACE inhibitor or angiotensin II receptor blockers, 
medications that might affect liver function (amiodarone, glucocorticoids, methotrexate, 
tamoxifen and other drugs), and medications that might affect glucose metabolism such as 
glucocorticoids. Acute and chronic inflammation was excluded on the basis of medical 
history, physical examination, and routine laboratory tests, including measurement of 
temperature and urinalysis.  
 All subjects were studied in the morning after an overnight fast. Basic anthropometric 
measurements were performed on all study subjects. Blood pressure was measured twice in 
the sitting position with a mercury sphygmomanometer after a resting period of 10 minutes 
and expressed in mmHg. Urinary albumin excretion rate (UAE) was measured from at least 
two 24-h urine samples and determined as the mean of 24-h urine collections. Patients 
performed collections on two consecutive days to minimize variability. Normoalbuminuria 
was defined as a UAE<30 mg/24h. Those with microalbuminuria (UAE≥30<300 mg/24h) and 
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macroalbuminuria (UAE≥300 mg/24h) were excluded from the study. Serum creatinine was 
measured in fasting blood sample. Data on serum creatinine levels, age, sex and race were 
used to calculate the estimated glomerular filtration rate (eGFR) using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formula (23), which has been shown to be 
accurate in determining renal function in diabetic patients with normal renal function. Those 
with chronic kidney disease, defined as the presence of impaired eGFR (less than 60 ml min
-1
 
1.73m
-2
),
 
were excluded from the study. 
 Fasting venous blood samples were collected in the morning between 08:00 and 09:30 
hours after an overnight fast for the determination of HbA1c, AST, ALT, GGT, ALK, total 
bilirubin, total, LDL, HDL cholesterol, and triglycerides. Microalbumin and HbA1c was 
measured spectrophotometrically by turbidimetric immuno-inhibition (Olympus AU600, 
Beckman-Coulter, USA). Glucose, cholesterol and triglycerides in serum were measured by 
an enzymatic colorimetric method. Complete blood count was determined on an automatic 
blood counter (Advia 120, Siemens Diagnostic Solutions, USA). AST, ALT, GGT, ALK, and 
total bilirubin were measured using standard laboratory methods.  
 The study protocol complies with the Declaration of Helsinki as well as with local 
institutional guidelines, and was approved by the local ethics committees. 
 Data are expressed as means ± SD for normally distributed values, as median with 
range for non-normally distributed values, and percentage. Pearson’s correlation coefficients 
were used to calculate correlations between normally distributed values and Spearman’s rank 
correlation coefficients were used for non-normally distributed values. To investigate the 
relation between NAFLD markers with renal function parameters data were also stratified in 
quartiles depending on UAE and serum creatinine and in different groups of eGFR. Kruskal-
Wallis test was used for calculating the significance of the trend for each variable among the 
different groups. Separate multivariate logistic regression models were used to assess 
 7 
associations of NAFLD markers and risk of progression of renal disease, taking in account of 
potential confounders. Two models were constructed for each marker: in model A, 
adjustments were made for age and sex; model B included further adjustment for duration of 
diabetes, HbA1c and BMI. Level of statistical significance was chosen to be α=0.05. 
Statistical analysis was performed by statistical package STATA/IC ver.11.1.  
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RESULTS: 
 
 The characteristics of the study subjects are listed in Table 1. Mean/median values of 
BMI, waist to hip ratio (WHR), HDL cholesterol, triglycerides, AST, ALT, ALK, GGT, 
bilirubin, serum creatinine, UAE, eGFR as well as blood pressure were within the normal 
range for patients with diabetes, with slightly elevated HbA1c and LDL cholesterol levels. 
Association of NAFLD associated markers with parameters of renal function are presented in 
Table 2. Serum creatinine was significantly associated with ALT, GGT and bilirubin, with 
bilirubin showing the strongest correlation (r=0.29, p<0.001). eGFR was significantly 
associated with ALK and bilirubin, with ALK showing the strongest correlation (r=0.23, 
p<0.001). Finally, UAE was significantly associated only with GGT (r=0.11, p=0.04). In 
addition, NAFLD associated markers and renal parameters significantly correlated with 
various metabolic variables, mainly with parameters included in diagnosis of metabolic 
syndrome (WHR, HbA1c, HDL cholesterol, triglycerides and blood pressure). The mentioned 
correlations were most significant for WHR.  
 Relationship between NAFLD markers among those in the 2
nd
, 3
rd
 and 4
th
 quartiles of 
serum creatinine compared to those in quartile 1 are presented in table 3. Stratifying NAFLD 
associated markers for the degree of serum creatinine, trends across quartiles of serum 
creatinine for ALT, GGT and bilirubin were statistically significant (all p<0.05). Subjects in 
the 4
th
 quartile of serum creatinine had significantly elevated ALT, GGT and bilirubin levels 
compared to subjects in 1
st
, 2
nd
, and 3
rd
 quartiles. We also explore relationship between 
NAFLD markers among those in the 2
nd
, 3
rd
 and 4
th
 quartiles of UAE compared to those in 
quartile 1 (<6.8 mg/24h). Stratifying NAFLD markers for degree of UAE, trends across 
quartiles was statistically significant only for ALK (p=0.03). Subjects in the 4
th
 quartile of 
UAE (≥16.6 mg/24h) had elevated levels of ALK (71 units/L (42-202)) compared to subjects 
in 1
st
 quartile (69 units/L (34-229)) (data not shown). 
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 Relationship between NAFLD markers among those subjects with normal, mild 
decreased renal function or with renal hyperfiltration are displayed in Table 4. Stratifying 
NAFLD associated markers for the degree of eGFR, trends across different groups for AST, 
ALK and bilirubin were statistically significant (all p<0.05). Subjects with eGFR ≥ 125 ml 
min
-1 
1.73m
-2
 had significantly higher levels of AST and ALK than subjects with an estimated 
GFR below 125 ml min
-1 
1.73m
-2
. In contrast, hyperfiltrating subjects had significantly lower 
levels of bilirubin than subjects with normal or mild decreased renal function. 
 In multivariate logistic regression analysis, after adjustment for age and sex, ALK was 
significantly associated with risk of progression of renal function measured with serum 
creatinine and eGFR in our subjects (p≤0.008), with odds ratios of 0.97 to 1.03 (Table 4, 
Model A). Odds ratio for ALK were attenuated slightly but remained significant after further 
adjustment for duration of diabetes, HbA1c and BMI (Table 4, Model B). 
 
 
 
 
 
 
 
 
 
 
 
 10
DISCUSSION 
 Previous studies documented that NAFLD is associated with an increased prevalence 
and incidence of CKD in diabetic subjects (13, 16, 17, 24). In the present study we found 
significant associations of NAFLD associated markers, including AST, ALT, ALK, GGT and 
bilirubin with parameters of renal function in normoalbuminuric type 1 diabetic patients with 
normal or mild decreased renal function. Furthermore, we demonstrated that concentrations of 
ALT, GGT and bilirubin worsened in parallel with increased in quartiles of serum creatinine 
and ALK with increased in quartiles of UAE. In addition, concentrations of AST and ALK 
were higher in hyperfiltrating subjects. Finally, in multivariate logistic regression analysis 
only ALK was significantly associated with renal function parameters, after adjustment for 
covariates. 
 The most obvious explanation for our findings is that higher NAFLD markers may 
reflect fatty change in the liver and the coexistence of metabolic syndrome, an atherogenic 
condition closely associated with NAFLD and development of renal disease. In correlation 
analysis majority of NAFLD markers and renal parameters significantly correlated with 
components of metabolic syndrome, most notably with WHR, a measure of obesity and better 
predictor of cardiovascular diseases than waist circumference and BMI (25). In addition, 
metabolic syndrome is an independent risk factor for CKD and NAFLD (2, 26). Insulin 
resistance is the central pathophysiological phenomenon of metabolic syndrome, and it has 
been shown that NAFLD markers are associated with insulin resistance in type 1 diabetes and 
that insulin resistance contributes to the progression of nephropathy in type 1 diabetes (27, 
28). It has been suggested that NAFLD may be involved in the pathogenesis of CKD through 
the systemic release of various proinflammatory and procoagulant mediators from steatotic 
liver including CRP, TNF-alfa, TGF-beta 1, PAI-1, interleukin-6, advanced glycated end-
products, and other pro-inflammatory cytokines (13). However, it has been shown that 
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NAFLD is associated with an increased prevalence of CKD in type 1 diabetes independently 
of metabolic syndrome (17, 24). Moreover, it has been demonstrated that patients with 
NAFLD and biopsy-proven NASH have decreased eGFR and abnormal albuminuria 
independently of insulin resistance and components of metabolic syndrome (29, 30). 
 Although AST, ALT and GGT are the most commonly elevated enzymes found in 
patients with NAFLD (1, 4, 8), some patients with biopsy proven NAFLD may present with 
an isolated elevation of ALK instead of the more typical liver enzymes (7). In our study we 
observed that ALK levels were significantly higher in subjects in the highest quartile of UAE 
compared to those in lowest quartile, and that only ALK was associated with disturbances of 
renal function parameters, after adjustment for covariates. It is possible that ALK is 
associated with albuminuria in type 1 diabetes through pathogenic mediators from the liver, 
including proinflammatory cytokines, who are documented to disrupt the glomerular 
endothelial glycocalyx leading to microalbuminuria (31). In addition, it has been shown that 
urinary ALK has a potential value in the diagnosis of nephropathy in diabetes (32), and that 
ALK was an independent risk factor for cardiac death in subjects with advanced CKD (33). 
Moreover, we have previously observed that insulin resistance, the most important antecedent 
of microalbuminuria, was independently associated with ALK in type 1 diabetes (27).  
 In multivariate logistic regression analysis we found that ALK levels tend to be higher 
in patients with lower serum creatinine levels and in those with higher eGFR, which seems to 
be contradictory to the previous studies indicating that higher ALK levels are not associated 
with worsening of renal function. However, the levels of ALK was especially increased in 
hyperfiltrating subjects. Hyperfiltration in type 1 diabetes is associated with ultrastructural 
changes and increased risk of developing diabetic nephropathy and usually precedes changes 
in albuminuria by several years (34, 35). Moreover, kidney lesion in obesity, condition 
associated with NAFLD, is characterized by hyperfiltration and cosequent glomerulomegalia, 
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podocyte hypertrophy and intracellular accumulation (36). In addition, fat not only 
accumulate in the liver, but also in the kidney and may play a role in glomerular and tubular 
changes leading to hyperfiltration (36, 37). It was also suggested that glomerular 
hyperfiltration may be considered as a new marker of metabolic risk (38). It is obvious that 
hyperfiltration is associated with the higher risk of developing diabetic nephropathy and may 
mask a pathological decline in glomerular function.  
 The present study has a number of potential limitations. First, our study was cross-
sectional, which limited our ability to infer a causal relation between NAFLD markers and 
risk for the progression of renal disease in type 1 diabetes. Second, our study is limited by the 
unavailability of performing liver biopsy, the “gold standard” procedure for diagnosis of 
NAFLD. However, most of our patients with the higher serum markers of liver damage, 
including ALT, AST and ALK, had ultrasound-proven fatty liver that may be reasonable 
noninvasive surrogate measures (11, 39), although full histological spectrum of NAFLD may 
be present in subjects with normal liver enzymes (40). Third, we used estimated GFR rather 
than more precise measures of kidney function. Fourth, our analyses were based on 
measurement of UAE, serum creatinine and eGFR on two consecutive days that may not 
reflect the relation over time. According to these limitations, our results can probably be 
considered as conservative estimates of the relationship between NAFLD markers and renal 
function in normoalbuminuric type 1 diabetic patients. 
 In conclusion, we have shown that NAFLD associated markers, including ALT, AST, 
ALK, GGT and bilirubin are associated with renal function parameters in normoalbuminuric 
type 1 diabetic patients. Elevated liver markers might reflect liver fatty and consequent 
pathophysiological changes predating the development of renal disease in the context of the 
metabolic syndrome, an atherogenic condition closely associated with both NAFLD and 
kidney disease. In fact, we found that majority of NAFLD and renal markers significantly 
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correlated with metabolic parameters included in the diagnosis of metabolic syndrome (WHR, 
HbA1c, HDL cholesterol, triglycerides and blood pressure). After adjustment for covariates 
only ALK was associated with progression of renal disease measured with serum creatinine 
and eGFR. Whether the detection of elevated ALK levels in normoalbuminuric type 1 
diabetic patients has predictive value for development of renal disease needs to be assessed in 
further follow-up studies. 
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Table 1: Clinical and metabolic characteristics of all patients 
 
                                             
          VARIABLE                                     VALUE 
Age (years)                            34 (18-65)  
Duration of diabetes (years)                      12 (1-42) 
Body mass index (kg/m
2
)                            24 (15-37) 
Waist to hip ratio                                         0.81±0.07  
Fasting glucose (mmol/L)                           5.4 (2.7-10.2) 
Hemoglobin A1c (%)                                  7.43±1.63  
Systolic blood pressure (mmHg)                 120 (79-180) 
Diastolic blood pressure (mmHg)                80 (50-100) 
Total cholesterol (mmol/L)                       5.0±0.8 
LDL cholesterol (mmol/L)                       2.8±0.7   
HDL cholesterol (mmol/L)                       1.7±0.4  
Triglycerides (mmol/L)                      0.91 (0.3-4.1) 
AST (units/L)                                              20 (10-146) 
ALT (units/L)                                              19 (7-171) 
ALK (units/L)                                              69 (11-229) 
GGT (units/L)                                              16 (7-553) 
Bilirubin (µmol/L)                                       12 (5-103) 
Ferritin (µg/L)                                              55 (5-697) 
Serum creatinine (µmol/L)                          71±14  
eGFR (ml min
-1
 1.73m
-2
)                             106±16 
Urinary albumin excretion (mg/24h)           11.0 (1.7-29.8) 
eGFR, estimated glomerular filtration rate. 
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Table 2: Spearman correlation analysis of associations of NAFLD markers and renal function 
parameters with metabolic parameters 
  Variable               AST       ALT        ALK      GGT      bilirubin    creatinine   UAE    eGFR 
Duration of diab.   0.04       0.03        -0.06        0.14*      -0.04           0.00         0.14*    -0.29*   
BMI                       0.07       0.05         0.13*       0.01         0.13*        0.15*      -0.02     -0.10 
WHR                     0.14*     0.25*        0.25*      0.37*       0.16*         0.39*       0.01      -0.02 
HBA1c                  0.06       0.11*        0.14*      0.11*       -0.13*       -0.14*      0.07       0.15* 
Total cholesterol   0.01       0.05          0.02        0.16*       -0.14*        -0.01        0.02     -0.21* 
LDL cholesterol   -0.08      0.07          0.05         0.14*       -0.81          0.08         0.03     -0.18* 
HDL cholesterol   0.01      -0.11*       -0.13*      -0.03        -0.09         -0.19*     -0.13*   -0.17* 
Triglycerides        0.02       0.18*         0.19*       0.23*       -0.03          0.07        0.11*     0.06 
Systolic BP          0.06        0.09          0.12*       0.13*       0.08           0.11*      0.09      -0.08 
Diastolic BP        -0.05       0.02          0.16*      0.11*        0.03            0.08        0.23*     -0.01  
Serum creatinine   0.01       0.16*   0.01      0.18*        0.29*      
eGFR                     0.05       0.01          0.23*    -0.01        -0.12*      
UAE                     -0.05       0.04          0.06      0.11*        0.03     
BMI, body mass index; WHR, waist to hip ratio; HbA1c, hemoglobin A1c; GFR, estimated 
glomerular filtration rate; UAE, urinary albumin excretion rate 
*P<0.05 
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Table 3: Quartiles of serum creatinine  
                          1st quartile          2nd quartile           3rd quartile          4th quartile            P 
                       (<63 µmol/L)           (≥63<71)                 (≥71<80)        (≥80 µmol/L)     for trend                         
AST (units/L)  20 (10-146)      20 (12-113)            19 (12-143)       21 (12-55)          0.3 
ALT (units/L)  18 (9-146)      19 (7-69)    18 (8-171)       23 (10-120)        0.007 
ALK (units/L) 68 (34-208)      66 (36-125)   69 (25-229)       71 (11-120)        0.7 
GGT (units/L)  14 (8-213)      15 (7-117)    17 (7-553)       18 (8-100)          0.006 
Bil. (µmol/L)   10 (5-43)      12 (6-31)    13 (5-46)       14 (7-113)         <0.001 
Bil, bilirubin. 
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Table 4: Levels of NAFLD markers depending on level of estimated glomerular filtration rate  
                                             
    Variable                  eGFR >60≤90        eGFR >90≤125           eGFR >125            P 
                                                                   ml min
-1
 1.73m
-2                                                 
 
AST (units/L)               18 (12-42)                20 (10-143)             21 (13-146)           0.02 
ALT (units/L)               18 (8-58)                   20 (7-171)               20 (10-146)          0.1 
ALK (units/L)               64(11-120)                68 (34-202)             81 (38-229)          <0.001 
GGT (units/L)              15 (7-48)                   16 (7-753)                16 (8-54)              0.5 
Bilirubin (µmol/L)       13 (7-46)                   13 (5-113)                9 (5-28)                0.02 
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Table 5: Multivariate logistic regression analysis of NAFLD markers with risk of progression    
    of renal disease in type 1 diabetes 
 Independent                                                              
   variable             Group                         Model A                                Model B 
 AST            1                        1.00 (0.98-1.02)       1.00 (0.98-1.02) 
                                  2                        0.98 (0.96-1.00)                     0.98 (0.96-1.00) 
                                  3                        1.00 (0.98-1.02)                     0.99 (0.97-1.02) 
 ALT            1                         1.01 (0.99-1.02)             1.01 (0.99-1.02) 
                                  2                        0.99 (0.97-0.99)                     1.00 (0.98-1.01) 
                                  3                        0.98 (0.97-1.00)                     0.98 (0.96-0.99) 
 ALK             1                       1.00 (0.99-1.01)             1.00 (0.99-1.01) 
                                   2                       0.98 (0.97-0.99)*                   0.98 (0.97-0.99)* 
                                   3                       1.01 (1.00-1.03)*                   1.02 (1.00-1.03)* 
 GGT   1                      1.01 (0.99-1.02)        1.00 (0.99-1.02) 
                                   2                      0.99 (0.99-1.00)                       0.99 (0.99-1.00) 
                                   3                     0.99 (0.99-1.00)                        0.99 (0.99-1.00)  
 Bilirubin            1                       0.99 (0.96-1.02)              0.99 (0.97-1.02) 
                                   2                      1.03 (0.99-1.07)                       1.03 (0.99-1.07) 
                                   3                      0.97 (0.93-1.00)                      0.97 (0.94-1.01) 
Group1: urinary albumin excretion rate; Group 2: serum creatinine; Group 3: estimated 
glomerular filtration rate. 
Data are OR (95% CI) from separate models. Model A adjusted for age and sex; model B 
adjusted for age, sex, duration of diabetes, BMI and HbA1c.  
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*P < 0.05. 
 
